Conference Correspondent

Conference Correspondent | September 24, 2019
Researchers report promising findings for a novel quad regimen, D-RVd, compared with RVd in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem-cell transplant.
Conference Correspondent | September 24, 2019
A retrospective analysis suggests improved survival outcomes with selinexor plus dexamethasone compared with standard treatments in triple-class relapsed or refractory multiple myeloma (RRMM).
Conference Correspondent | September 24, 2019
New data suggest that combinations using a subcutaneous (SC) co-formulation of daratumumab with recombinant human hyaluronidase have similar clinical activity and safety as intravenous daratumumab in patients with newly diagnosed multiple myeloma (MM).
Conference Correspondent | September 24, 2019
This first-in-human study shows that AMG 420, a BiTE antibody that directs the immune system to target B-cell maturation antigen (BCMA) on the tumor cell and CD3 on T-cells, may be effective and safe.
Conference Correspondent | September 24, 2019
Researchers report positive data for patients with relapsed or refractory multiple myeloma (RRMM) and extramedullary disease in the phase 2 HORIZON study of melflufen plus dexamethasone.
Conference Correspondent | September 24, 2019
This phase 1 study demonstrates that CT053, a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell product, is effective and safe in patients with multiply relapsed multiple myeloma (MM).
Conference Correspondent | September 24, 2019
This study reports successful administration of intravenous daratumumab over 90 minutes for patients with relapsed or refractory multiple myeloma (RRMM).
Conference Correspondent | December 17, 2018
New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy.
Conference Correspondent | December 17, 2018
Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL).
Conference Correspondent | December 17, 2018
The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL).
Page 1 of 4
Results 1 - 10 of 33

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code